Drugs & Therapy Perspectives

, Volume 34, Issue 7, pp 335–343 | Cite as

Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting

  • Fernando Velasco-Juanes
  • Juan Carlos Gómez-Esteban
  • Tamara Fernández-Valle
  • Alexandra Matute-Nieves
  • Javier Almeida-Velasco
  • Mar Irida Lloret-Villas
  • Iratxe Ugarriza-Serrano
Original Research Article



OnabotulinumtoxinA (OnabotA) appears to be an effective prophylactic treatment for chronic migraine (CM), but its use in patients with episodic migraine (EM) has been little explored. We set out to assess the clinical efficacy of OnabotA in a real-life setting, focusing particularly on EM patients.


This is a longitudinal, prospective, single-center analysis of 115 migraine patients [70 with CM, 21 with low-frequency EM (LFEM), and 24 with high-frequency EM (HFEM)] who received OnabotA in routine clinical practice in 2005–2015. In this study, the dosage regimen, the number of headaches, impact on quality of life (HIT-6 impact test) and the adverse events were among the parameters assessed.


OnabotA treatment significantly reduced the number of headaches experienced by CM and EM patients, also increasing the number of responders (> 50% reduction in headache days). The quality of life of EM patients improved significantly, reducing the HIT-6 scores in both LFEM and HFEM patients. Adverse events were reported in 40% of patients, always mild and transient.


OnabotA is an effective and safe prophylactic treatment for migraine in routine clinical practice. It significantly improves a patients’ quality of life, particularly that of those suffering from CM and HFEM.


Compliance with ethical standards

Conflict of interest

Writing and editorial assistance was provided by Dr Mark Sefton (BiomedRed SL) and funded by Allergan S.A. All authors met the ICMJE authorship criteria and received neither honoraria nor payments for authorship. None of the authors have any conflict of interest to declare.

Ethical approval

All procedures involving human participants were performed in accordance with institutional and/or national research committee ethical standards and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all the participants in the study.


  1. 1.
    Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14:1. Scholar
  2. 2.
    World Health Organization. headache disorders fact sheet no. 277, 2016.
  3. 3.
    World Health Organization. Lifting The burden, atlas of headache disorders and resources in the world 2011.
  4. 4.
    Stovner LJ, Colette A. On behalf of the Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain. 2008;9:139–46.CrossRefGoogle Scholar
  5. 5.
    Berg J. Economic evidence in migraine and other headaches: a review. Eur J Health Econ. 2004;5:s43–54.CrossRefGoogle Scholar
  6. 6.
    Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders. Cephalalgia. 2013;33:629–808.CrossRefGoogle Scholar
  7. 7.
    Torres-Ferrús M, Quintana M, Fernandez-Morales J, et al. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37:104–13.CrossRefGoogle Scholar
  8. 8.
    Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–68.CrossRefGoogle Scholar
  9. 9.
    Bigal ME. The paradoxical effects of analgesics and the development of chronic migraine. Arq Neuropsiquiatr. 2011;69:544–51.CrossRefGoogle Scholar
  10. 10.
    Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76:711–8.CrossRefGoogle Scholar
  11. 11.
    Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86–92.CrossRefGoogle Scholar
  12. 12.
    Blumenfeld A, Varon S, Wilcox T, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301–15.CrossRefGoogle Scholar
  13. 13.
    Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–66.CrossRefGoogle Scholar
  14. 14.
    Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–32.CrossRefGoogle Scholar
  15. 15.
    Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9:285–98.CrossRefGoogle Scholar
  16. 16.
    Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55:103–22.CrossRefGoogle Scholar
  17. 17.
    BOTOX® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. Allergan, Irvine. 2013.Google Scholar
  18. 18.
    Gooriah R, Ahmed F. Therapeutic uses of botulinum toxin. J Clin Toxicol. 2015;5:225. Scholar
  19. 19.
    Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord. 2011;17:S28–33.CrossRefGoogle Scholar
  20. 20.
    Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358–73.CrossRefGoogle Scholar
  21. 21.
    Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.CrossRefGoogle Scholar
  22. 22.
    Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache J Head Face Pain. 2010;50:921–36.CrossRefGoogle Scholar
  23. 23.
    Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.CrossRefGoogle Scholar
  24. 24.
    Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307:1736–45.CrossRefGoogle Scholar
  25. 25.
    Robertson C, Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat. 2012;8:35–48.CrossRefGoogle Scholar
  26. 26.
    Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–14.CrossRefGoogle Scholar
  27. 27.
    Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.CrossRefGoogle Scholar
  28. 28.
    Pedraza MI, de la Cruz C, Ruiz M, et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. SpringerPlus 2015 [cited 2016 May 11];4. Available at:
  29. 29.
    Khalil M, Zafar HW, Quarshie V, et al. Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54. Scholar
  30. 30.
    Ahmed F, Zafar HW, Buture A, et al. Does analgesic overuse matter? Response to onabotulinumtoxinA in patients with chronic migraine with or without medication overuse. SpringerPlus. 2015;4:589. Scholar
  31. 31.
    Negro A, Curto M, Lionetto L, et al. A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1. Scholar
  32. 32.
    Yang M, Rendas-Baum R, Varon SF, et al. Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011;31:357–67.CrossRefGoogle Scholar
  33. 33.
    Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: table 1: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.CrossRefGoogle Scholar
  34. 34.
    Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache J Head Face Pain. 2009;49:1153–62.CrossRefGoogle Scholar
  35. 35.
    Diener H-C, Bussone G, Van Oene J, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.CrossRefGoogle Scholar
  36. 36.
    Mitsikostas DD, Rapoport AM. New players in the preventive treatment of migraine. BMC Med. 2015;13:279. Scholar
  37. 37.
    Edvinsson J, Warfvinge K, Edvinsson L. Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type a: an organ culture study. J Headache Pain. 2015;16:555. Scholar
  38. 38.
    Cernuda-Morollón E, Ramón C, Martínez-Camblor P, et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156:820–4.CrossRefGoogle Scholar
  39. 39.
    Ezpeleta D, Rosich P, editors. Guía oficial de práctica clínica en cefaleas 2015. Guías Oficiales de la Sociedad Española de Neurología. 5th ed. Madrid: Luzán; 2015.Google Scholar
  40. 40.
    Lipton RB, Rosen NL, Ailani J, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia. 2016;36:899–908.CrossRefGoogle Scholar
  41. 41.
    Rothrock JK, Scanlon C, Weibelt S. OnabotulinumtoxinA for the treatment of chronic migraine: long-term outcome [abstract]. In: American Headache Association Meeting; 2011.Google Scholar
  42. 42.
    Cernuda-Morollon E, Ramon C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. 2015;35:864–8.CrossRefGoogle Scholar
  43. 43.
    Blumenfeld AM, Aurora SK, Laranjo K, et al. Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015;15:100. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Fernando Velasco-Juanes
    • 1
  • Juan Carlos Gómez-Esteban
    • 1
  • Tamara Fernández-Valle
    • 1
  • Alexandra Matute-Nieves
    • 1
  • Javier Almeida-Velasco
    • 1
  • Mar Irida Lloret-Villas
    • 1
  • Iratxe Ugarriza-Serrano
    • 1
  1. 1.Neurology DepartmentHospital Universitario CrucesBarakaldoSpain

Personalised recommendations